Scheibler Lukas's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed May 31, 2022
- Accession no.
- 0001127602-22-016013
- Filed
- May 31, 2022
- Trade date
- Apr 21-May 27, 2022
- Filing delay
- 40 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $430.0K. It was filed 40 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scheibler LukasCIK 0001651281 | Officer (CHIEF INNOVATION OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | JOtherDisposed | −1,875 | $0.00 | $0 | 50,358 | Direct | |
| May 27, 2022 | Common Stock | SSaleDisposed | −10,000 | $43.00 | −$430,000 | 40,358 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | JOtherDisposed | −11,250 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.